Prostate Cancer
News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.
News | Patient Positioning Radiation Therapy | September 08, 2017
September 8, 2017 — Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U....
News | Patient Positioning Radiation Therapy | September 05, 2017
September 5, 2017 — Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC)...
Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.
News | Radiopharmaceuticals and Tracers | August 16, 2017
August 16, 2017 — In the featured translational article in the August issue of The Journal of Nuclear Medicine,...
News | Biopsy Systems | July 17, 2017
July 17, 2017 — Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical...
News | Patient Positioning Radiation Therapy | June 28, 2017
June 28, 2017 — Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR hydrogel...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney
News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.
Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.
This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.
Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.
News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017
News | Prostate Cancer | May 24, 2017
May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...
News | Radiopharmaceuticals and Tracers | May 15, 2017
May 15, 2017 — Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be...
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal...
Multiparametric MRI (MpMRI) has proved helpful in enhancing biopsy sampling for prostate cancer when combined with ultrasound.
Feature | Prostate Cancer | April 10, 2017 | By Jeff Zagoudis
While prostate cancer is one of the most common cancers among American men — the third leading cause of cancer deaths...
News | Prostate Cancer | April 04, 2017
April 4, 2017 — Profound Medical Corp. announced that the first TULSA-PRO patient paid procedure has been successfully...
News | Biopsy Systems | March 30, 2017
March 30, 2017 — Analogic Corp. announced that it will introduce its bkFusion solution for improving biopsy targeting...
News | Focused Ultrasound Therapy | March 29, 2017
March 29, 2017 — EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU...
News | Radiation Therapy | March 27, 2017
March 27, 2017 — Radiation therapists and physicians know that education can reduce anxiety before radiation treatment...
News | Biopsy Systems | March 23, 2017
March 23, 2017 — Urology specialists at the Barbara Ann Karmanos Cancer Institute (Detroit) have begun using the UroNav...
News | Prostate Cancer | March 22, 2017
March 22, 2017 — Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO...
News | Biopsy Systems | March 16, 2017
March 16, 2017 — Exact Imaging has received Health Canada approval and the corresponding medical device license (#98667...
CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.
News | Radiopharmaceuticals and Tracers | March 16, 2017
March 16, 2017 — The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine...
News | Prostate Cancer | March 09, 2017
March 9, 2017 — Michigan Medicine and the University of Michigan have launched the nation’s first prostate cancer risk...
